Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

959
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
959
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

554
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
554
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

576
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
576

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once-Daily Tacrolimus Formulations: The BITACORA Study.

Clinical transplantation·2026
Same author

Single-cell and multi-omic characterization of ex vivo expanded ASTRLs from stable kidney transplant recipients reveals a regulatory T cell phenotype.

Scientific reports·2026
Same author

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Blood advances·2026
Same author

SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.

Blood research·2025
Same author

[Biomarkers of oxidative stress and inflammation in contrast-associated acute kidney injury].

Anales del sistema sanitario de Navarra·2024
Same author

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Blood cancer journal·2024

Related Experiment Video

Updated: Feb 6, 2026

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

906

Update on posttransplant lymphoproliferative disease.

Paloma L Martin-Moreno1, Carlos Panizo2

  • 1Nephrology Department.

Current Opinion in Nephrology and Hypertension
|August 30, 2018
PubMed
Summary

Posttransplant lymphoproliferative disorder (PTLD), linked to Epstein-Barr virus (EBV), significantly impacts patient and graft outcomes. Recent research offers improved diagnostic accuracy and therapeutic strategies, notably rituximab and T-cell therapies.

More Related Videos

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.8K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.5K

Related Experiment Videos

Last Updated: Feb 6, 2026

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

906
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.8K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.5K

Area of Science:

  • Transplant immunology
  • Oncology
  • Virology

Background:

  • Posttransplant lymphoproliferative disorder (PTLD) is a severe complication following organ or stem cell transplantation.
  • Epstein-Barr virus (EBV) is a common co-factor in PTLD development, impacting patient prognosis.
  • PTLD significantly affects patient survival and graft success rates.

Purpose of the Study:

  • To review recent advancements in understanding and managing PTLD.
  • To highlight updated knowledge on PTLD epidemiology, prophylaxis, diagnosis, and treatment.
  • To focus on the last 18 months of published research.

Main Methods:

  • Literature review of studies published in the last 18 months.
  • Analysis of recent findings on PTLD classification and diagnostics.
  • Evaluation of current and emerging therapeutic approaches.

Main Results:

  • Improved understanding of PTLD epidemiology and risk factors.
  • Enhanced diagnostic accuracy for EBV viral load and PTLD classification (WHO).
  • Rituximab-based therapies show promise in treatment, with adoptive T-cell therapy as a potential alternative.

Conclusions:

  • Continued research is essential to reduce PTLD incidence.
  • Development of more accurate diagnostic tools is crucial.
  • Novel therapeutic strategies are improving treatment outcomes for PTLD patients.